Quarterly ResultAug 6, 2026, 07:27 AM
GH Research Q2 Loss $15.1M; Cash & Equivalents $345.1M
AI Summary
GH Research PLC reported a net loss of $15.1 million for the second quarter of 2026 and $34.1 million for the first six months of the year, reflecting increased research and development activities. The company maintained a strong liquidity position with $345.1 million in cash and cash equivalents as of June 30, 2026, bolstered by $111.2 million in net proceeds from an April 2026 share offering. Operationally, GH Research achieved significant milestones, including FDA alignment on Phase 3 plans for GH001, completion of two Phase 1 trials, and the grant of a new U.S. patent for its mebufotenin therapies.
Key Highlights
- Reported a loss of $15.1 million for the three months ended June 30, 2026, compared to $9.3 million in Q2 2025.
- Six-month loss for 2026 was $34.1 million, up from $20.1 million in the same period of 2025.
- Cash and cash equivalents stood at $345.1 million as of June 30, 2026, up from $246.3 million at year-end 2025.
- Marketable securities were $17.6 million as of June 30, 2026.
- Net proceeds from the April 2026 ordinary share offering were $111.2 million.
- Received written responses from the FDA confirming CMC and device plans appear Phase 3 ready for GH001.
- Completed GH001-HV-106 and GH001-HV-109 Phase 1 clinical trials.
- U.S. Patent No. 12,685,721 was granted for methods of treating MDD and TRD with mebufotenin.
Price Impact
More from GHRS